In 2023, Lakefront Biotherapeutics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Lakefront Biotherapeutics has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2023 | 2022 |
|---|---|---|
Total Scope 1 | 2,922a | 3,180a |
Total Scope 2 | ||
Market-Based | 173a | 217a |
Location-Based | 1,132a | 849a |
Total Scope 3 | 36,537a | 54,609a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of Lakefront Biotherapeutics amounted to 4,054 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Lakefront Biotherapeutics increased by 0.62%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2023, the total Scope 1 emissions of Lakefront Biotherapeutics were 2,922 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2022), Lakefront Biotherapeutics's Scope 1 emissions decreased by 8.11%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2023, Lakefront Biotherapeutics reported Scope 2 greenhouse gas (GHG) emissions of 173 tCO₂e using the market-based method and 1,132 tCO₂e using the location-based method.a
Compared to the previous year (2022), Lakefront Biotherapeutics's Scope 2 emissions (Location-Based) rose by 33.33% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2023, Lakefront Biotherapeutics reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2023, Lakefront Biotherapeutics reported 36,537 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2023 disclosure of Lakefront Biotherapeutics includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2023, Lakefront Biotherapeutics reported total Scope 3 emissions of 36,537 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 99.95% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.05% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2022), Lakefront Biotherapeutics's Scope 3 emissions decreased by 33.09%, highlighting the company's efforts to lower indirect emissions from its value chain.a
In 2023, Lakefront Biotherapeutics reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2023, the largest contributors to Lakefront Biotherapeutics's Scope 3 emissions were:a
In 2023, Lakefront Biotherapeutics reported a total carbon footprint of 40,591 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 30.78% decrease compared to 2022, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Lakefront Biotherapeutics's total carbon footprint was Scope 3 emissions, accounting for 90.01% of the company's total carbon footprint, followed by Scope 1 emissions at 7.2%.a